Piedmont Investment Advisors Inc. raised its stake in Omnicell, Inc. (NASDAQ:OMCL) by 8.3% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 10,195 shares of the company’s stock after buying an additional 781 shares during the period. Piedmont Investment Advisors Inc.’s holdings in Omnicell were worth $824,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Manchester Capital Management LLC purchased a new position in Omnicell during the 1st quarter valued at about $49,000. Great West Life Assurance Co. Can boosted its holdings in Omnicell by 4.9% during the 1st quarter. Great West Life Assurance Co. Can now owns 55,069 shares of the company’s stock valued at $4,447,000 after acquiring an additional 2,570 shares during the period. JPMorgan Chase & Co. boosted its holdings in Omnicell by 716.6% during the 1st quarter. JPMorgan Chase & Co. now owns 225,620 shares of the company’s stock valued at $18,239,000 after acquiring an additional 197,990 shares during the period. Oregon Public Employees Retirement Fund boosted its holdings in Omnicell by 1.8% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 15,347 shares of the company’s stock valued at $1,241,000 after acquiring an additional 277 shares during the period. Finally, Redwood Investments LLC boosted its holdings in Omnicell by 70.3% during the 1st quarter. Redwood Investments LLC now owns 225,476 shares of the company’s stock valued at $18,227,000 after acquiring an additional 93,114 shares during the period. Institutional investors own 97.32% of the company’s stock.
OMCL stock opened at $81.10 on Monday. The company has a current ratio of 1.96, a quick ratio of 1.47 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $3.34 billion, a price-to-earnings ratio of 53.01, a P/E/G ratio of 2.63 and a beta of 1.20. Omnicell, Inc. has a 1 year low of $45.15 and a 1 year high of $86.87.
In other Omnicell news, Director Joanne B. Bauer sold 3,798 shares of the stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $81.72, for a total value of $310,372.56. Following the sale, the director now owns 20,314 shares of the company’s stock, valued at approximately $1,660,060.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Scott Peter Seidelmann sold 8,500 shares of the firm’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $81.68, for a total value of $694,280.00. Following the sale, the executive vice president now directly owns 28,929 shares in the company, valued at approximately $2,362,920.72. The disclosure for this sale can be found here. Insiders sold a total of 179,464 shares of company stock worth $13,515,291 in the last ninety days. 2.77% of the stock is owned by corporate insiders.
OMCL has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Omnicell from a “hold” rating to a “buy” rating and set a $72.00 target price for the company in a report on Tuesday, January 29th. BidaskClub cut Omnicell from a “buy” rating to a “hold” rating in a report on Thursday, January 31st. Piper Jaffray Companies restated a “neutral” rating and set a $70.00 target price on shares of Omnicell in a report on Friday, February 8th. They noted that the move was a valuation call. ValuEngine upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Finally, Dougherty & Co raised their target price on Omnicell from $78.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, March 7th. Five equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $79.89.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Featured Story: What is the 52-week high/low?
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.